Podcasts about aimmune therapeutics

SEASON: 5 EPISODE: 5Episode Overview:Crisis can strike at any moment. Are you or your business crisis capable? My guest today will share with us strategies and tactics to become crisis capable, how we can build our capacity to survive, and succeed in every environment. She will also be sharing her key messages on how to approach negotiations as relationship-building opportunities, how to think through scenarios and formulate a plan in advance, how to notice details that others may overlook, how to leverage your EQ to remain calm and navigate difficult conversations, and how to lean into your intuition and follow any hunch.Fabiana is a passionate advocate for negotiation, and she is committed to helping others to develop the skills they need to succeed in any situation.Please join me for my interesting conversation with Fabiana-Lacerca-Allen.Guest Bio: Fabiana Lacerca-Allen is the Senior Vice President of Compliance at Aimmune Therapeutics, a Nestle Health Science corporation, a biopharmaceutical company developing treatments for potentially life-threatening food allergies.Practicing law and compliance for more than 30 years, Lacerca-Allen's passion as a compliance leader stems from values instilled in her at an early age and have helped to shape her career path as a global thought leader in law and compliance. In addition to leading the compliance team at Aimmune, Lacerca-Allen serves as a member of the Board of Directors and an audit Committee member at Shield Therapeutics plc.Lacerca has a track record of building and implementing successful compliance programs across Fortune 100 organizations, particularly within pharmaceutical, biotech and medical device industries. Her expertise includes negotiating and implementing corporate integrity agreements, deferred prosecution agreements and consent decrees for U.S. corporations with extensive global operations.Prior to her roles at Aimmune , Lacerca-Allen was the Senior Vice President and Chief Compliance Officer at Elan where she had global responsibilities in strategic initiatives and implementation of compliance programs. And prior to this, she held roles as a Board Member at ArthroCare, Senior Vice President and Chief Compliance Officer at Mylan, Director of Compliance at Bristol Myers & Squibb and Senior Counsel at Microsoft.Resource Links:Website: https://fabianalacercaallen.com/Product Link: https://www.amazon.com/Crisis-Capable-Building-Capacity-Environment-ebook/dp/B0D9BY131HInsight Gold Timestamps:03:02 We're all going to die, so don't worry about it. Worry about what you're going to live for04:24 You overheard a conversation with your father 06:04 He said, That's why you should only get information when you can do something about it07:54 Most people follow action09:45 Somebody asked me, How do you choose people to work with?11:43 I think intuition is important, as a marker to pay more attention14:05 D on't collect regrets17:29 There's no situation that's not a win win, that's sustainable19:58 Your bottom line is, you have to be willing to walk out of anything, period23:18 One typical mistake I found23:50 We have more in common than not25:21 What are the three things that people that don't like you will tell me about you? 28:25 I say, Act with integrity and accept the results30:16 The book is called Crisis Capable, Building Your...

Welcome to our new six-episode series: C. difficile: Preparing the Field for Change. This program will explore how to take a patient-centered approach to treatment and diagnosis, explore emerging treatment options, and discuss best practices for transitions of care. In this episode, Drs. Paul Feuerstadt and Sahil Khanna are joined by guest Dr. Jessica Allegretti to discuss FMT and new microbiome therapies. You can now claim CME for listening – visit agau.gastro.org. This series is supported by educational grants from Aimmune Therapeutics, Inc., Seres Therapeutics, and Ferring Pharmaceuticals, Inc.

Welcome to our new six-part series: C. difficile: Preparing the Field for Change. This program will explore how to take a patient-centered approach to treatment and diagnosis, explore emerging treatment options, and discuss best practices for transitions of care. In this episode, Drs. Paul Feuerstadt and Sahil Khanna cover risk factors for initial and recurrent C. difficile infection. This episode was originally released as a bonus episode in November 2022. You can now claim CME for listening – visit agau.gastro.org. This series is supported by educational grants from Aimmune Therapeutics, Inc., Seres Therapeutics, and Ferring Pharmaceuticals, Inc.

Welcome to our new six-episode series: C. difficile: Preparing the Field for Change. This program will explore how to take a patient-centered approach to treatment and diagnosis, explore emerging treatment options, and discuss best practices for transitions of care. In this episode, Drs. Paul Feuerstadt and Sahil Khanna are joined by guests Rebecca Perez and Cheri Lattimer to discuss case management and transitions of care in C. difficile infection. You can now claim CME for listening – visit agau.gastro.org. This series is supported by educational grants from Aimmune Therapeutics, Inc., Seres Therapeutics, and Ferring Pharmaceuticals, Inc.

Welcome to our new six-episode series: C. difficile: Preparing the Field for Change. This program will explore how to take a patient-centered approach to treatment and diagnosis, explore emerging treatment options, and discuss best practices for transitions of care. In this episode, Drs. Paul Feuerstadt and Sahil Khanna are joined by guests Drs. Kevin Garey and Melissa Passarello to discuss the impact of recurrent CDI on patients and their lives. This episode does not offer Continuing Medical Education (CME) credits. This series is supported by educational grants from Aimmune Therapeutics, Inc., Seres Therapeutics, and Ferring Pharmaceuticals, Inc.

Welcome to our new six-episode series: C. difficile: Preparing the Field for Change. This program will explore how to take a patient-centered approach to treatment and diagnosis, explore emerging treatment options, and discuss best practices for transitions of care. In this episode, Drs. Paul Feuerstadt and Sahil Khanna describe the shifts in the microbiota with C. difficile infection. This episode was originally released as a bonus episode in November 2022. You can now claim CME for listening – visit agau.gastro.org. This series is supported by educational grants from Aimmune Therapeutics, Inc., Seres Therapeutics, and Ferring Pharmaceuticals, Inc.

Welcome to our new six-episode series: C. difficile: Preparing the Field for Change. This program will explore how to take a patient-centered approach to treatment and diagnosis, explore emerging treatment options, and discuss best practices for transitions of care. In this episode, Drs. Paul Feuerstadt and Sahil Khanna are joined by guest Dr. Colleen Kelly to discuss how to reconcile guideline differences for testing and treatment of C. difficile. You can now claim CME for listening – visit agau.gastro.org. This series is supported by educational grants from Aimmune Therapeutics, Inc., Seres Therapeutics, and Ferring Pharmaceuticals, Inc.

This episode we are excited to welcome to the podcast Danielle Duran, Director of GxP Compliance and Training at Aimmune Therapeutics! As fellow advocates for education and continuous enablement in life sciences, Dori and Danielle share their insights on the current state of learning in our industry, and where we can do better to support more effective outcomes in IT and Quality organizations.Listen in now to learn more a bout leveraging effective learning to support quality culture, shifting towards effectiveness measures of training, and, perhaps most importantly, moving towards a people-centric learning model as part core business operations.Enjoy the episode and please don't forget to rate, subscribe and share! *Disclaimer: Podcast guest participated in the podcast as an individual subject matter expert and contributor. The views and opinions they share are not necessarily shared by their employer. Nor should any reference to specific products or services be interpreted as commercial endorsements by their current employer.This is a production of ProcellaRX

Even the best-laid food allergy school accommodation plans can go awry. If challenges happen, parents and caregivers need to pivot. FAACT's General Counsel and Vice President of Civil Rights Advocacy, Amelia Smith, JD, shares tips and ideas for finding school solutions. To keep you in the know:Back-to-School Accommodations: 504 Refresher PodcastFAACT's Civil Rights Advocacy PodcastsOperational Guidance for K-12 Schools and Early Care and Education Programs to Support Safe In-Person LearningFrequently Asked Questions for K-12 and Early Care and Education (ECE) Settings: Information for School ECE Administrators, Teachers, Staff and ParentsLetter to Educators and Parents Regarding New CDC Recommendations and their impacts on Children - March 24, 2022FAACT's Civil Rights Advocacy Resource CenterFAACT Civil Rights Advocacy - Section 504 ResourcesFAACT-recognized Food Allergy Support GroupsDepartment of Education, Section 504 Frequently Asked Questions Contact Amelia Smith at Amelia.Smith@FoodAllergyAwareness.org.You can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher, iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube.  Contact us directly via Email.Sponsored by: Aimmune Therapeutics

We're discussing the impact of current Covid-19 guidelines and protocols on students with food allergies as we take a deeper dive into the basics of K-12 school accommodations with FAACT's General Counsel and Vice President of Civil Rights Advocacy, Amelia Smith, JD. Tips for handling accommodation violations and how to explain the severity of food allergy are a few highlights to expect in this information-packed podcast.To keep you in the know, here are a few links to topics mentioned in the podcast:Operational Guidance for K-12 Schools and Early Care and Education Programs to Support Safe In-Person LearningFrequently Asked Questions for K-12 and Early Care and Education (ECE) Settings: Information for School ECE Administrators, Teachers, Staff and ParentsLetter to Educators and Parents Regarding New CDC Recommendations and their impacts on Children - March 24, 2022FAACT's Civil Rights Advocacy Resource CenterFAACT Civil Rights Advocacy - Section 504 Resources (Sample accommodations, sample parental/caregiver letters, sample doctor/allergist letters, and more)FAACT's Civil Rights Advocacy PodcastsFAACT-recognized Food Allergy Support GroupsDepartment of Education, Section 504 Frequently Asked QuestionsContact Amelia Smith at Amelia.Smith@FoodAllergyAwareness.orgYou can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher, iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube.  Contact us directly via Email.Sponsored by: Aimmune Therapeutics

In this episode, three parents of students participating in OIT share their accommodation successes and challenges as they navigate school during treatments. Emile Baker, Stephanie Lemmey, and FAACT's General Counsel and Vice President of Civil Rights Advocacy, Amelia Smith, JD, authentically share their journey as they highlight tips for handling school and their own child's emotions. If you are considering OIT, this is a MUST-listen to podcast.To keep you in the know, here are a few links to topics mentioned in the podcast:OIT: What to Expect Pre, Post, and During Treatments with Dr. Brian VickeryBack To School: Fall 2021 Readiness - Understanding 504 Plans and Accommodations PodcastFAACT's Section 504 PlansFAACT's Civil Rights Advocacy Resource Center You can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher,  iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram, LinkedIn, Pinterest, and YouTube. Contact us directly via Email.Sponsored by:  Aimmune Therapeutics* Please note that today's guest was not sponsored by Aimmune Therapeutics or compensated in any way by the sponsor to participate in this specific podcast.

In this episode, we get down to the basics to help you  get ready for a great return to school! We are sitting down with FAACT's General Counsel and Vice President of Civil Rights Advocacy, Amelia Smith, JD, to help us dust off our accommodations skills and to re-visit the basics for success.To keep you in the know, here are some helpful links:Special Note: Please contact Amelia.Smith@FoodAllergyAwareness.org directly if you are experiencing challenges regarding 504 accommodations or receiving meals, which are no longer safe and appropriate for your student. FAACT's Civil Rights Advocacy Resource Center | American with Disabilities ActFAACT's Sample Parental Referral LetterFAACT's Sample Accommodations for 504/IEP/IHPFAACT's Find a Support Group Near You AASA The School Superintendents Association: FAACT's Guest Blog on COVID-19 and Students with Food AllergiesFAACT's Podcast Ep. 26: COVID-19 Back-To-School Must Knows - Featuring Amelia Smith, JD.FAACT's Podcast Ep. 12: Civil Rights Advocacy - Responding to the CDC's Interim Guidance and Meals in the Classroom - Featuring Amelia Smith, JDFAACT's Position Statement and Letter to the CDC regarding CDC's Interim Guidance and Meals in the ClassroomYou can find the FAACT Roundtable Podcast on Pandora, Apple Podcast, Spotify, Google Podcast, Stitcher, iHeart Radio, Podcast Chaser, Deezer, and Listen Notes.Visit us at www.FoodAllergyAwareness.org and follow us on Facebook, Twitter, Instagram,  & Pinterest.Sponsored by: Aimmune Therapeutics

In this episode, Ayesha talks about Nestlé's marketing of Seres Therapeutics' oral microbiome drug for recurrent C. Difficile infection (CDI). CDIs are the leading cause of hospital-acquired infections in the US, with recurrence being a common problem. It typically develops after the use of antibiotics which can wipe out the gut's healthy bacteria. Seres' microbiome drug SER-109 aims to restore the healthy bacteria via an oral capsule that contains a protective species of gut bacteria. Nestlé has been a big player in the gastrointestinal space and first partnered with Seres in 2016. The latest venture of the partnership will have the food and beverage giant utilize its global pharmaceutical business Aimmune Therapeutics to take on the role of lead commercialization party for the oral microbiome drug.The team also discussed the World Health Organization's (WHO) adding IL-6 receptor blockers to its treatment guidelines for severely and critically ill COVID-19 patients. This includes IL-6 blockers from Roche (Actemra) and Sanofi (Kevzara). While IL-6 receptor antagonists initially met with mixed results in COVID-19 trials, recent data suggests it can cut improve survival outcomes in critically ill patients. The WHO also called on manufacturers to reduce the cost of the IL-6 receptor monoclonal antibodies to help increase access to the drugs in low- and middle-income countries.Read the full articles here: Nestlé to Market Seres' Oral Microbiome Drug for C. Difficilev WHO Calls on Roche and Sanofi to Lower Costs for Life-Saving COVID-19 Treatment For more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

合作邀約: onthewaytowork2020@gmail.com IG: @onthe_waytowork 歡迎大家來跟我們聊聊天https://www.instagram.com/onthe_waytowork/ 瑞士食品巨頭雀巢（Nestle）在北美週一時間宣布收購花生過敏藥物製造商Aimmune Therapeutics的74.4%股份，雀巢出價每股34.50美元，較Aimmune上周五收盤價溢價174%。但這次的協議價格仍是比Aimmune Therapeutics 52週以來的高點還低了7%。Aimmune的花生過敏治療藥物Palforzia讓患者接觸很小劑量的花生蛋白，處方藥慢慢加重劑量，並與其他食物混合，以增強抵抗力。 今年1月獲得美國FDA批准用於兒童。該交易將在第四季度完成。 上次講到健身手環，Amazon的Halo，今天來看看對手Walmart的新動作，Walmart推出了全新會員制度Walmart+，一年會費98塊美金。 昨天跟大家分享到聯合航空（United Airlines）宣布永久取消國內航班的改票費，不到一天，美國另兩大航空公司美國航空（American Airlines）和達美航空（Delta Air Lines）也宣布相同政策，準備開始這個航空業搶客大戰。 ***今天分享的兩個podcast頻道: Techmeme ride home & WSJ minute briefing 如果喜歡的話 歡迎幫我們分享和按讚 Powered by Firstory Hosting

Nestlé bulks up its health-science unit with acquisition of Aimmune Therapeutics. First direct commercial flight takes place between Israel and U.A.E. Former Georgetown University basketball coach John Thompson dies at 78. Learn more about your ad choices. Visit megaphone.fm/adchoices

Major U.S. stock indexes gained ground in August. Apple, Tesla shares jump after stock splits. United Airlines shares drop after end of flight-change fee. Aimmune Therapeutics shares skyrocket on news of Nestlé deal. J.R. Whalen reports. Learn more about your ad choices. Visit megaphone.fm/adchoices

Nestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its fast-growing health science business. Nestle set up Nestle Health Science (NHS) in 2011 to open up a new area of business between food and pharma. Nestle in a statement said that its offer for Aimmune values the California-based biopharmaceutical firm, which it has been working with since 2016 and in which it already has a stake of around 25.6%, at $2.6 billion. --- This episode is sponsored by · Afrolit Podcast: Hosted by Ekua PM, Afrolit shares the stories of multi-faceted Africans one episode at a time. https://open.spotify.com/show/2nJxiiYRyfMQlDEXXpzlZS?si=mmgODX3NQ-yfQvR0JRH-WA Support this podcast: https://anchor.fm/newscast-africa/support

Returning guest, Dr. Steve Tilles, Senior Director of Medical Affairs at Aimmune Therapeutics, the first company to gain FDA approval of a peanut allergy treatment, PALFORZIA™, discusses his experience as an allergist, where the allergy immunology market is headed over the next year and provides real-world insight into practices reopening in light of COVID-19.

Welcome to the Great Women in Compliance Podcast, co-hosted by Lisa Fine and Mary Shirley. In this episode, Mary Shirley visits with Fabiana Lacerca-Allen, the Senior Vice President of Compliance at Aimmune Therapeutics, a biopharmaceutical company developing treatments for potentially life-threatening food allergies. Practicing law and compliance for more than 25 years, Lacerca’s passion as a compliance leader stems from values instilled in her at an early age and have helped to shape her career path as a global thought leader in law and compliance. We start the episode off with a bang as Fabiana recalls how her fascinating childhood informed her first lessons in Compliance. With three attempts made to kidnap her as a child, Fabiana is no stranger to the risk to physical safety and shares with us her tips for when she travels alone on business. Don’t miss the article Fabiana co-authored on this topic for more information: https://hispanicexecutive.com/self-defense-white-paper/ Fabiana also shares her approach to leadership and building a team around you – a tribe of people that you want to have with you throughout even the toughest of times – the people you’d be willing to have with you during a kidnapping – or Coronavirus lockdown! Relatedly, Mary and Fabiana discuss the concept of mentorship as a two way street and Fabiana discusses how she fosters her mentorship relationships to ensure that the benefits are maximized for both parties. We end this episode with a nod to self-care and some surprising results of award programs in schools that can provide us with food for thought regarding Compliance program incentives. Join the Great Women in Compliance community on LinkedIn here.

A wave of vaping related illnesses has resulted in at least seven deaths. Here's what people should know about vaping health risks and the potential impact on cannabis companies. Also, Aimmune Therapeutics peanut allergy pill clears an important hurdle, putting it on track toward an FDA approval. Can this medicine be a blockbuster or will safety concerns curb its appeal? 

Dr. Steve Tilles, Senior Director of Medical Affairs at Aimmune Therapeutics, a biopharmaceutical company developing treatments for life-threatening food allergies, discusses the company’s lead candidate AR101, CODIT (Characterized Oral Desensitization Immunotherapy) approach to treating food allergies and the broader food allergy landscape. Visit www.hpr.fm to listen to more interviews about healthcare and research findings

Today in FirstWord:

Today in FirstWord:

This is not trading/investment adviceFor good background on the PALISADE trial and Aimmune Therapeutics, check out my prior blog post: https://breakingbiotech.com/2017/10/09/going-nuts-for-oral-immunotherapy-aimt/-MDGL drop this week on no news is a buying opportunity, if you haven't taken a position-ADMS drop has more merit. I'm waiting to see what they say about this paragraph IV notice https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm047676.htm#p3-Aimmune Therapeutics shows very solid Phase 3 data for their desensitization therapy and treatment AR101 https://www.aimmune.com/

Today in FirstWord:

It’s a food problem that can prove fatal - and we might be about to crack it. The first licensed medicines to treat peanut allergy are close to being approved by regulators. But we ask – why has it taken so long? For over a century we’ve known that an allergy can be treated by controlled exposure to the allergen. Simply put, the treatment of a peanut allergy is a very small dose of peanut. So when the prevalence of allergies began to soar in the 1990s you could have been forgiven for thinking a solution might not be far off. But as yet, there are no licensed medicines for widespread use. Some clinicians already use the technique – known as immunotherapy – but it is unregulated and the cost is prohibitive for many. This could all be about to change. Two treatments are expected to be approved by regulators in the next couple of years. It couldn't have happened without the involvement of charitable donors, venture capitalists, and pharmaceutical companies. The food industry has also invested millions. In this episode we explore the relationship between profit and progress when it comes to solving a serious food health problem. Why has it taken until now to get to this point? And, when the worst possible outcome is the death of a child, isn’t total avoidance of peanuts the safest option? Contributors: Dr Louisa James, Queen Mary University of London, Lisa and Clara Goff, Dr Andrew Clark, Cambridge Peanut Allergy Clinic and Chief Scientific Officer, Camallergy, Dr Pierre-Henri Benhamou, DBV technologies, Stephen Dilly, Aimmune Therapeutics, and Dr Robert Wood, John Hopkins Children’s Centre. Presenter: Emily Thomas

Today in FirstWord: